Some are cheering Obamacare exchange glitches as proof that millions will buy health insurance. Irrational exuberance?
This biopharmaceutical stock is on fire -- and these 3 catalysts could crank up the heat even more.
Consolidating the home infusion market continues to offer mixed results for investors due to margin concerns.
With New York and Vermont charging the same premiums under Obamacare regardless of age, it'll be interesting to see whether participation rates are different there.
Residents around the country will face much different costs, and future actions from insurers such as Aetna and Cigna and service providers such as Health Management Associates and Universal Health could change the dynamics again.
A big decision by this state will leave $79 billion federally funded dollars on the table and could keep 2.5 million low-income citizens from getting health insurance. Will its decision limit Obamcare's chance of success?
These states give health-care insurance customers the best rates, and low costs might explain why UnitedHealth, Cigna, and Aetna haven't taken full advantage of the Obamacare opportunity.
Amarin's focus on the fundamentals of running a biotech business pays off.
UnitedHealth, WellPoint, and other health insurers have seen their stocks jump over the past year, but they've given back some ground lately. Is Obamacare to blame?
Will ObamaCare fundamentally change how managed-care companies like UnitedHealth, Cigna, Aetna, and WellPoint operate?